Pharmaceuticals - Spain

Spain

In 2024, the projected revenue in the Pharmaceuticals market in Spain is estimated to reach €13.94bn.
The largest market within the industry is Oncology Drugs, which is expected to have a market volume of €2.62bn in 2024.
It is anticipated that the revenue in this market will experience an annual growth rate of 5.78% (CAGR 2024-2028), resulting in a market volume of €17.45bn by 2028.
When compared to global figures, it is worth noting that United States is expected to generate the highest revenue, amounting to €590.60bn in 2024.
Spain has seen a surge in the demand for generic drugs, as the government pushes for cost-saving measures in the pharmaceutical sector.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Pharmaceuticals market in Spain has been showing significant growth in recent years.

Customer preferences: Customers in Spain are increasingly demanding a wider range of pharmaceutical products and services. They are looking for innovative and effective treatments for various diseases. Additionally, customers are becoming more health-conscious, leading to an increase in demand for preventative healthcare products.

Trends in the market: The Spanish pharmaceuticals market is experiencing a shift towards more specialized and high-value products. There is a growing demand for biotech drugs, which are used to treat complex diseases such as cancer and autoimmune disorders. Moreover, the market is seeing an increase in the use of digital health technologies, such as telemedicine and health apps, which are becoming more popular among consumers.

Local special circumstances: Spain has a well-developed healthcare system, with both public and private healthcare providers. The public healthcare system is funded by the government and covers the majority of the population. However, there is also a growing private healthcare sector, which is attracting more customers. Additionally, Spain has a large aging population, which is driving demand for healthcare products and services.

Underlying macroeconomic factors: Spain's economy has been growing steadily in recent years, which has led to an increase in disposable income and consumer spending. This has resulted in higher demand for pharmaceutical products and services. Moreover, the Spanish government has been investing in the healthcare sector, which has led to the development of new healthcare facilities and technologies. Additionally, Spain is a member of the European Union, which has created a favorable regulatory environment for the pharmaceutical industry.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.